Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine

President Donald Trump’s stock transaction filings reveal multiple purchases of Moderna ($MRNA) during March 2026, followed by a partial sale on May 18. Since those trades, the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously to recommend Moderna's investigational mRNA influenza vaccine, mFLUSIVA, for adults aged 50 and older, with the agency's final approval decision expected by August 5.

• The filings show Trump purchased Moderna ($MRNA) on March 2 ($15,001-$50,000) and again on March 17 ($1,001-$15,000), before reporting a $1,001-$15,000 sale on May 18.
• Moderna ($MRNA) has gained roughly 49% since Trump's March 2 purchase and 46% since his March 17 purchase.
• The FDA advisory committee voted 9-0 that the benefits of Moderna's mRNA flu vaccine outweigh the risks for adults 50-64 and adults 65 and older.
• The FDA has set an August 5, 2026 PDUFA target date for its final approval decision.
• Lobbying disclosures show Moderna remained active in Washington throughout 2026 on vaccine, public health, and FDA-related policy, with quarterly federal lobbying expenditures continuing at six-figure levels as the company pursued regulatory approvals and commercialization efforts.

Relevant Companies

• Moderna ($MRNA) – FDA approval of mFLUSIVA would expand the company's commercial respiratory vaccine portfolio.
• Pfizer ($PFE) – Competes in the influenza vaccine market and broader vaccine industry.
• GSK ($GSK) – Major seasonal influenza vaccine manufacturer that could face additional competition if Moderna's product is approved.

Editor’s Note: This is a developing story. This article may be updated as more details become available.